United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $482.03, for a total transaction of $4,000,849.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $21,774,259.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

United Therapeutics Stock Down 0.4%

UTHR stock opened at $490.24 on Friday. United Therapeutics Corporation has a 52-week low of $375.61 and a 52-week high of $609.35. The firm has a market cap of $21.03 billion, a P/E ratio of 17.54, a PEG ratio of 2.46 and a beta of 0.56. The company’s 50-day simple moving average is $527.06 and its 200-day simple moving average is $539.91.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.41 EPS. On average, analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: The FDA accepted United Therapeutics’ supplemental new drug application seeking to expand the label for nebulized Tyvaso to treat idiopathic pulmonary fibrosis (IPF). The filing is supported by Phase 3 TETON-1 and TETON-2 data, which showed statistically significant lung-function improvement and reduced clinical worsening. FDA review is expected to conclude in late April 2027. A successful expansion could substantially increase Tyvaso’s addressable market. FDA Accepts UTHR’s sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with United Therapeutics carrying a consensus “Moderate Buy” rating and an average price target of about $646, although some firms have reduced their targets and Morgan Stanley’s target is near the current trading range. This signals long-term optimism but also highlights valuation and execution concerns.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.69 million, reducing her direct ownership by 2.84%. EVP Paul Mahon separately sold 8,300 shares for about $4.00 million, cutting his position by 15.52%. The transactions may reinforce near-term investor caution, although Rothblatt’s sale was disclosed as occurring under a pre-arranged trading plan. United Therapeutics Insider Sale Filing
• Negative Sentiment: United Therapeutics’ second-quarter results showed Tyvaso revenue declining 4% year over year, with management citing competition across nebulized Tyvaso, Tyvaso DPI and Remodulin. The IPF opportunity is strategically important because investors are looking for growth to offset weakness in the existing pulmonary hypertension business.

Wall Street Analyst Weigh In

UTHR has been the subject of several research analyst reports. Morgan Stanley set a $515.00 target price on United Therapeutics in a research note on Thursday, August 6th. Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System boosted its stake in shares of United Therapeutics by 55,526.2% in the second quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock worth $18,036,953,000 after acquiring an additional 33,229,108 shares during the last quarter. BlackRock Inc. purchased a new position in United Therapeutics in the 2nd quarter valued at $2,868,735,000. Avoro Capital Advisors LLC boosted its stake in United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after buying an additional 295,221 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.